// App-Quantinova.ai

5011 : Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.

Researchers

Presenter

  • Anthony Victor D'Amico

Principal Investigators

  • Wanling Xie

  • Elizabeth McMahon

  • Marian Loffredo

  • Shana Medeiros

  • David John Joseph

  • James William Denham

  • David S Lamb

  • Parvesh Kumar

  • Glenn Bubley

  • Molly A. Sullivan

  • Richard Hellwig

  • Juan Carlos Vera

  • Rolf Freter

  • W. Jeffrey Baker

  • Jeffrey Y.C. Wong

  • Andrew A. Renshaw

  • Philip W. Kantoff

Medical Centers

  • Dana-Farber Cancer Center/Brigham and Women's Hospital, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Brigham and Women's Hospital, Brookline, MA

  • Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

  • Sir Charles Gairdner Hospital, Perth, Australia

  • Univ. of Newcastle, Callaghan, Australia

  • University of Otago, Dunedin, New Zealand

  • Box 454009, Las Vegas, NV

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Cape Cod Hosp, Hyannis, MA

  • St Anne's Hospital, Fall River, MA

  • Jamaica Plain VA Medical Center, Boston, MA

  • DFCI South Shore Hospital Cancer Center, Scituate, MA

  • Onc Assoc, Hartford, CT

  • City of Hope, Duarte, CA

  • Baptist Hospital and Miami Cancer Institute, Miami, FL

  • Department of Surgery, Gynecologic Service, Memorial Sloan-Kettering Cancer Center, New York, NY

Locations

  • United States

  • Australia

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • III

Study Id's

  • NCT00116142

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved